Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002036 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00002036: Completed Phase 1 study, sponsored by Abbott.
NCT00002036 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002036, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
Interventions
- DRUG Anti-HIV Immune Serum Globulin (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Phase | Phase 1 |
What the finished NCT00002036 record still lists
NCT00002036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Anti-HIV Immune Serum Globulin (Human) is the first listed.
NCT00002036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002036 about?
NCT00002036 is a clinical study titled "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)". To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
What is the current status of trial NCT00002036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants.
What interventions are being tested in trial NCT00002036?
The interventions under investigation include: Anti-HIV Immune Serum Globulin (Human) (DRUG).
Who is sponsoring clinical trial NCT00002036?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002036's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning